From global intelligence to CMC handoff, every Agent owns a stage of the biopharma value chain — and they share data, memory, and Skills across the workflow.
A glance tells you which agent owns which stage.
InBeacon scans the global biopharma landscape every hour — regulatory filings, clinical trials, deals, patents — and routes signals to your team.
InPrism answers your questions across millions of papers and regulatory guidance, side-by-side comparing FDA · NMPA · EMA · ICH.
InAnvil evaluates molecules at design time for purification feasibility, aggregation, characterizability — before you commit downstream resources.
InForge turns that design into a Phase-appropriate CMC process: chromatography, formulation, characterization, document drafts.
The four are connected. A pipeline event in InBeacon can flag a competitor's molecule, which you can compare to yours in InPrism, evaluate in InAnvil, and develop a process for in InForge — without leaving the platform or duplicating data.
Enough depth to decide; not the full detail page yet.
Hourly scans of the global biopharma landscape. Regulatory · trials · deals · patents — cross-source dedup, pushed to your watchlist.
Ask in plain language; get paragraph-cited answers. FDA · NMPA · EMA · ICH side-by-side on the same topic.
5 Design modules + 6 Evaluation modules. Sort manufacturability the moment a sequence is ready.
A CMC process copilot trained on Inscinstech CMC v2.2 plus FDA review docs. 21 CFR Part 11-ready.
Every Agent reads from a shared knowledge graph and writes to shared memory. Skills migrate. Outputs become inputs.
InBeacon pushes a competitor's Phase 3 failure → InPrism analyzes their process route → InAnvil scores your candidate's relative strengths → InForge outputs an accelerated process plan.
InPrism finds a key paper → auto-extracts the molecule sequence → feeds it to InAnvil developability scoring → InForge recommends a purification strategy.
InBeacon detects a new FDA guidance → InPrism diffs the key changes → InForge auto-drafts an SOP update.